vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and CORE MOLDING TECHNOLOGIES INC (CMT). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $74.7M, roughly 1.0× CORE MOLDING TECHNOLOGIES INC). On growth, CORE MOLDING TECHNOLOGIES INC posted the faster year-over-year revenue change (19.5% vs -16.8%). Over the past eight quarters, CORE MOLDING TECHNOLOGIES INC's revenue compounded faster (-2.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Core Molding Technologies, Inc. was founded in 1988 and now based in Columbus, Ohio. The company manufactures sheet molding compounds (SMC), and molds fiberglass reinforced plastics. It occupies over 1,000,000 square feet of manufacturing space and its main subsidiaries are in Matamoros, Mexico, Gaffney, South Carolina, and Cincinnati, Ohio. In 2011, Core Molding Technologies formed Core Specialty Composites, LLC.

BIOX vs CMT — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.0× larger
BIOX
$77.6M
$74.7M
CMT
Growing faster (revenue YoY)
CMT
CMT
+36.3% gap
CMT
19.5%
-16.8%
BIOX
Faster 2-yr revenue CAGR
CMT
CMT
Annualised
CMT
-2.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
CMT
CMT
Revenue
$77.6M
$74.7M
Net Profit
$-7.4M
Gross Margin
46.8%
15.2%
Operating Margin
9.3%
4.8%
Net Margin
-9.6%
Revenue YoY
-16.8%
19.5%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CMT
CMT
Q4 25
$74.7M
Q3 25
$77.6M
$58.4M
Q2 25
$79.2M
Q1 25
$60.6M
$61.4M
Q4 24
$98.8M
$62.5M
Q3 24
$93.3M
$73.0M
Q2 24
$88.7M
Q1 24
$84.0M
$78.1M
Net Profit
BIOX
BIOX
CMT
CMT
Q4 25
Q3 25
$-7.4M
$1.9M
Q2 25
$4.1M
Q1 25
$-1.6M
$2.2M
Q4 24
$605.2K
Q3 24
$-6.2M
$3.2M
Q2 24
$6.4M
Q1 24
$9.8M
$3.8M
Gross Margin
BIOX
BIOX
CMT
CMT
Q4 25
15.2%
Q3 25
46.8%
17.4%
Q2 25
18.1%
Q1 25
39.4%
19.2%
Q4 24
42.0%
15.8%
Q3 24
40.2%
16.9%
Q2 24
20.0%
Q1 24
50.8%
17.0%
Operating Margin
BIOX
BIOX
CMT
CMT
Q4 25
4.8%
Q3 25
9.3%
4.4%
Q2 25
6.6%
Q1 25
1.5%
4.6%
Q4 24
14.5%
1.4%
Q3 24
2.5%
4.9%
Q2 24
8.4%
Q1 24
15.7%
6.1%
Net Margin
BIOX
BIOX
CMT
CMT
Q4 25
Q3 25
-9.6%
3.2%
Q2 25
5.1%
Q1 25
-2.6%
3.6%
Q4 24
0.6%
Q3 24
-6.6%
4.3%
Q2 24
7.2%
Q1 24
11.6%
4.8%
EPS (diluted)
BIOX
BIOX
CMT
CMT
Q4 25
$0.35
Q3 25
$-0.12
$0.22
Q2 25
$0.47
Q1 25
$-0.02
$0.25
Q4 24
$0.00
$-0.01
Q3 24
$-0.10
$0.36
Q2 24
$0.73
Q1 24
$0.14
$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CMT
CMT
Cash + ST InvestmentsLiquidity on hand
$15.5M
$38.1M
Total DebtLower is stronger
$17.6M
Stockholders' EquityBook value
$288.3M
$158.2M
Total Assets
$734.9M
$228.1M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CMT
CMT
Q4 25
$38.1M
Q3 25
$15.5M
$42.4M
Q2 25
$43.2M
Q1 25
$38.5M
$44.5M
Q4 24
$29.2M
$41.8M
Q3 24
$32.3M
$42.3M
Q2 24
$37.8M
Q1 24
$16.4M
$26.6M
Total Debt
BIOX
BIOX
CMT
CMT
Q4 25
$17.6M
Q3 25
$18.2M
Q2 25
$18.8M
Q1 25
$19.2M
Q4 24
$19.7M
Q3 24
$20.2M
Q2 24
$20.6M
Q1 24
$21.1M
Stockholders' Equity
BIOX
BIOX
CMT
CMT
Q4 25
$158.2M
Q3 25
$288.3M
$155.4M
Q2 25
$153.5M
Q1 25
$345.0M
$149.9M
Q4 24
$346.3M
$147.4M
Q3 24
$346.0M
$147.8M
Q2 24
$147.5M
Q1 24
$348.5M
$142.8M
Total Assets
BIOX
BIOX
CMT
CMT
Q4 25
$228.1M
Q3 25
$734.9M
$219.7M
Q2 25
$219.9M
Q1 25
$798.2M
$223.6M
Q4 24
$835.2M
$209.6M
Q3 24
$827.3M
$220.7M
Q2 24
$225.7M
Q1 24
$836.1M
$212.3M
Debt / Equity
BIOX
BIOX
CMT
CMT
Q4 25
0.11×
Q3 25
0.12×
Q2 25
0.12×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
0.14×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CMT
CMT
Operating Cash FlowLast quarter
$14.4M
$5.0M
Free Cash FlowOCF − Capex
$-2.9M
FCF MarginFCF / Revenue
-3.9%
Capex IntensityCapex / Revenue
10.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CMT
CMT
Q4 25
$5.0M
Q3 25
$14.4M
$4.6M
Q2 25
$3.5M
Q1 25
$23.3M
$6.1M
Q4 24
$-5.4M
$5.0M
Q3 24
$5.2M
$9.2M
Q2 24
$15.9M
Q1 24
$-17.4M
$5.1M
Free Cash Flow
BIOX
BIOX
CMT
CMT
Q4 25
$-2.9M
Q3 25
$-346.0K
Q2 25
$880.0K
Q1 25
$4.3M
Q4 24
$509.0K
Q3 24
$7.0M
Q2 24
$13.0M
Q1 24
$3.2M
FCF Margin
BIOX
BIOX
CMT
CMT
Q4 25
-3.9%
Q3 25
-0.6%
Q2 25
1.1%
Q1 25
7.0%
Q4 24
0.8%
Q3 24
9.6%
Q2 24
14.6%
Q1 24
4.1%
Capex Intensity
BIOX
BIOX
CMT
CMT
Q4 25
10.7%
Q3 25
8.4%
Q2 25
3.3%
Q1 25
2.9%
Q4 24
7.2%
Q3 24
3.1%
Q2 24
3.3%
Q1 24
2.4%
Cash Conversion
BIOX
BIOX
CMT
CMT
Q4 25
Q3 25
2.44×
Q2 25
0.86×
Q1 25
2.79×
Q4 24
-8.85×
Q3 24
2.92×
Q2 24
2.47×
Q1 24
-1.78×
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons